Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Azilect Rasagiline mesylate Parkinson?s disease Complete
Banzel Rufinamide Lennox-Gastaut syndrome List with clinical criteria and/or conditions Complete
Baqsimi glucagon Severe hypoglycemic reactions Reimburse with clinical criteria and/or conditions Complete
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete
Basaglar Insulin glargine Diabetes mellitus, type 1; diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Bavencio Avelumab metastatic Merkel Cell Carcinoma (mMCC) Reimburse with clinical criteria and/or conditions Complete
Bavencio Avelumab Urothelial Carcinoma (UC) Complete
Beleodaq Belinostat Withdrawn
Benlysta Belimumab systemic lupus erythematosus Do not reimburse Complete
Benlysta Belimumab Systemic lupus erythematosus Do not list Complete